Xeljanz Lawsuit Filed Over Failure to Warn About Risk of Blood Clots, Pulmonary Embolisms
Pfizer allegedly knew about the blood clot risks with Xeljanz, but misled patients and the medical community in order to maximize profits.
Pfizer allegedly knew about the blood clot risks with Xeljanz, but misled patients and the medical community in order to maximize profits.
The manufacturer also expects the FDA to reject approval for the drug for the treatment of atopic dermatitis due to FDA safety cocerns.
The move comes after the FDA held up Rinvoq approvals for months due to concerns it carried similar cancer and heart risks as Xeljanz.
The approvals come after new warnings about Xeljanz and Rinvoq side effects, which have been linked to cancer, blood clots and heart problems.